Patents by Inventor Alexander Hegmans

Alexander Hegmans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclosporine analogue molecules modified at amino acid 1 and 3
    Patent number: 9714271
    Abstract: Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 25, 2017
    Assignee: ContraVir Pharmaceuticals, Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3
    Publication number: 20160207961
    Abstract: Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: July 21, 2016
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Cyclosporine analogue molecules modified at amino acid 1 and 3
    Patent number: 9200038
    Abstract: Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 1, 2015
    Assignee: Ciclofilin Pharmaceuticals Corp.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3
    Publication number: 20140142033
    Abstract: Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Application
    Filed: December 14, 2011
    Publication date: May 22, 2014
    Applicant: Isotechnika Pharma Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES
    Publication number: 20130190223
    Abstract: The compounds of the present invention are non-immunosupressive cyclosporine analogue molecules that are able to bind cyclophilin. Said compounds include a modified side chain of amino acid I of cyclosporin A, consisting of an oxyalkyl having substituents R?, R1 and R2, where R? is H or Acetyl; R1 is a saturated or unsaturated straight chain or branched aliphatic carbon chain; and R2 may be a hydrogen; a unsubstituted, N substituted or NN disubstituted amide; a N substituted or unsubstituted acyl protected amine; a carboxylic acid; a N substituted or unsubstituted amine; a nitrile; a ester; a ketone; a hydroxy, dihydroxy, trihydroxy or polyhydroxy alkyl; or a substituted or unsubstituted aryl.
    Type: Application
    Filed: July 3, 2009
    Publication date: July 25, 2013
    Applicant: ISOTECHNIKA PHARMA INC.
    Inventors: Alexander Hegmans, Bruce W. Fenske, David P. Czajkowski, Darren R. Ure, Shin Sugiyama, Dan J. Trepanier, David H. McGlade, Mark D. Abel
  • Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
    Patent number: 7579373
    Abstract: Pro-drug forms of linear polyamine-bridged platinum compounds and methods for their production and use are provided. The polyamine-bridge portion of the compounds is based on spermine or spermidine, and the central amines of the polyamine-bridge are chemically bonded to labile blocking groups. The presence of the blocking groups serves to minimize the toxicity of the Pt compounds upon administration. Selective removal of the blocking groups and release of the active, unblocked species occurs upon exposure to suitable environmental conditions.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: August 25, 2009
    Assignee: Virginia Commonwealth University
    Inventors: Nicholas Farrell, Alexander Hegmans, John D. Roberts
  • Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
    Publication number: 20030114433
    Abstract: Pro-drug forms of linear polyamine-bridged platinum compounds and methods for their production and use are provided. The polyamine-bridge portion of the compounds is based on spermine or spermidine, and the central amines of the polyamine-bridge are chemically bonded to labile blocking groups. The presence of the blocking groups serves to minimize the toxicity of the Pt compounds upon administration. Selective removal of the blocking groups and release of the active, unblocked species occurs upon exposure to suitable environmental conditions.
    Type: Application
    Filed: August 22, 2002
    Publication date: June 19, 2003
    Inventors: Nicholas Farrell, Alexander Hegmans, John D. Roberts